Combination of a task1/3 channel blocker with a norepinephrine reuptake inhibitor for the treatment of sleep apnea

Combinations of compounds of formula (I)

• in which
• the ring Q represents a piperazine or a diazaheterobicyclic system of the formula
• in which * denotes the bond to the adjacent CHR′2 group and ** the bond to the carbonyl group,
• W1, W2 or W3 represents CH or N,
• R′1 represents halogen, cyano, (C1-C4)-alkyl, cyclopropyl or cyclobutyl
• where (C1-C4)-alkyl may be up to trisubstituted by fluorine and cyclopropyl and cyclobutyl may be up to disubstituted by fluorine,
• and
• R′2 represents (C4-C6)-cycloalkyl in which a ring CH2 group may be replaced by —O—,
• or
• R′2 represents a phenyl group of the formula (a), a pyridyl group of the formula (b) or (c) or an azole group of the formula (d), (e), (f) or (g),
• in which *** marks the bond to the adjacent carbonyl group and
• R′3 represents hydrogen, fluorine, chlorine, bromine or methyl,
• R′4 represents hydrogen, fluorine, chlorine, bromine, cyano, (C1-C3)-alkyl or (C1-C3)-alkoxy,
• where (C1-C3)-alkyl and (C1-C3)-alkoxy may each be up to trisubstituted by fluorine,
• R′5 represents hydrogen, fluorine, chlorine, bromine or methyl,
• R′6 represents hydrogen, (C1-C3)-alkoxy, cyclobutyloxy, oxetan-3-yloxy, tetrahydrofuran-3-yloxy, tetrahydro-2H-pyran-4-yloxy, mono-(C1-C3)-alkylamino, di-(C1-C3)-alkylamino or (C1-C3)-alkylsulfanyl,
• where (C1-C3)-alkoxy may be up to trisubstituted by fluorine,
• R7 represents hydrogen, fluorine, chlorine, bromine, (C1-C3)-alkyl or (C1-C3)-alkoxy,
• R8A and R8B are identical or different and independently of one another represent hydrogen, fluorine, chlorine, bromine, (C1-C3)-alkyl, cyclopropyl or (C1-C3)-alkoxy
• where (C1-C3)-alkyl and (C1-C3)-alkoxy may each be up to trisubstituted by fluorine,
• R9 represents hydrogen, (C1-C3)-alkyl or amino
• and
• wherein in subformula (d)
• Y represents O, S or N(CH3),
• wherein in subformula (e) and (f)
• Y represents O or S,
• or
• R′2 represents an —OR10 or —NR11R12 group in which
• R10 represents (C1-C6)-alkyl, (C4-C6)-cycloalkyl or [(C3-C6)-cycloalkyl]methyl,
• R11 represents hydrogen or (C1-C3)-alkyl
• and
• R12 represents (C1-C6)-alkyl, (C3-C6)-cycloalkyl, phenyl or benzyl, 1-phenylethyl or 2-phenylethyl,
• where (C1-C6)-alkyl may be up to trisubstituted by fluorine,
• and
• where phenyl and the phenyl group in benzyl, 1-phenylethyl and 2-phenylethyl may be up to trisubstituted by identical or different radicals selected from the group consisting of fluorine, chlorine, methyl, ethyl, trifluoromethyl, methoxy, ethoxy, trifluoromethoxy and (trifluoromethyl)sulfanyl,
• or
• R11 and R12 are attached to one another and, together with the nitrogen atom to which they are bonded, form a pyrrolidine, piperidine, morpholine or thiomorpholine ring, or
• R11 and R12 are attached to one another and, together with the nitrogen atom to which they are bonded, form a tetrahydroquinoline ring of the formula (c) or a tetrahydroisoquinoline ring of the formula (d),
• in which ** marks the bond to the carbonyl group,
• and a noradrenaline reuptake inhibitor,
• and the salts, solvates and solvates of the salts thereof.